470,831 Shares in Sanofi (SNY) Purchased by Janus Henderson Group PLC
Janus Henderson Group PLC purchased a new stake in Sanofi (NYSE:SNY) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 470,831 shares of the company’s stock, valued at approximately $22,558,000.
Several other hedge funds also recently made changes to their positions in SNY. Fisher Asset Management LLC increased its stake in shares of Sanofi by 8.1% in the 2nd quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock valued at $653,419,000 after acquiring an additional 1,022,953 shares during the last quarter. BlackRock Inc. increased its stake in shares of Sanofi by 47.6% in the 2nd quarter. BlackRock Inc. now owns 2,235,422 shares of the company’s stock valued at $107,100,000 after acquiring an additional 720,523 shares during the last quarter. FMR LLC increased its stake in shares of Sanofi by 3.0% in the 2nd quarter. FMR LLC now owns 5,374,385 shares of the company’s stock valued at $257,487,000 after acquiring an additional 155,751 shares during the last quarter. Harbour Capital Advisors LLC increased its stake in shares of Sanofi by 4,691.0% in the 2nd quarter. Harbour Capital Advisors LLC now owns 119,775 shares of the company’s stock valued at $2,500,000 after acquiring an additional 117,275 shares during the last quarter. Finally, Aperio Group LLC increased its stake in shares of Sanofi by 17.8% in the 2nd quarter. Aperio Group LLC now owns 681,230 shares of the company’s stock valued at $32,638,000 after acquiring an additional 102,804 shares during the last quarter. 9.33% of the stock is owned by institutional investors.
A number of analysts have recently commented on the company. Cowen and Company reaffirmed a “market perform” rating and issued a $52.00 price target (up from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research note on Saturday, August 5th. Argus reaffirmed a “buy” rating and issued a $55.00 price target on shares of Sanofi in a research note on Friday, September 1st. Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research note on Friday, October 6th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $53.50.
In other Sanofi news, major shareholder Sanofi purchased 60,595 shares of the company’s stock in a transaction on Wednesday, August 23rd. The shares were purchased at an average cost of $478.98 per share, with a total value of $29,023,793.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 1.00% of the stock is currently owned by insiders.
Shares of Sanofi (SNY) opened at 49.53 on Thursday. The company’s 50-day moving average price is $49.46 and its 200-day moving average price is $48.26. Sanofi has a 1-year low of $36.81 and a 1-year high of $50.65. The company has a market capitalization of $124.39 billion, a PE ratio of 11.50 and a beta of 0.87.
Sanofi (NYSE:SNY) last issued its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The firm had revenue of $8.66 billion for the quarter, compared to analyst estimates of $8.71 billion. Sanofi’s revenue for the quarter was down 2.3% on a year-over-year basis. On average, equities analysts expect that Sanofi will post $3.32 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “470,831 Shares in Sanofi (SNY) Purchased by Janus Henderson Group PLC” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/10/19/470831-shares-in-sanofi-sny-purchased-by-janus-henderson-group-plc.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Stock Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related stocks with our FREE daily email newsletter.